Skip to main content

Table 1 Characteristics of the index pregnancies complicated by severe preeclampsia in 40 women with APS

From: Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients

Patient’s characteristics N = 40 (%)
Previous thrombotic events 14 (35.0)
Previous obstetric manifestations of APS 9 (22.5)
Known APS 12 (30.0)
Associated SLEa 11 (27.5)
Primiparous 21 (52.5)
Mean age at index pregnancy ± SD 30.5 ± 4.6
Antibody profile
 IgG/IgM anti-cardiolipin antibodies 34 (85.0)
 IgG/IgM anti-β2GPI antibodies 25 (62.5)
 LAC 33 (82.5)
 Triple-positive aPL antibody tests 21 (52.5)
Treatment during index pregnancy, before onset of preeclampsia
 Only LDA 4 (10.0)
 Only LMWH 4 (10.0)
 LDA + LMWH 15 (37.5)
 Hydroxychloroquine 7 (17.5)
 Glucocorticoids 8 (20.0)
 Immunosuppressants 3 (7.5)
 None 17 (42.5)
Features of severe preeclampsia
 Term at onset, weeks of gestation (median, IQR) 25.5 (23–29)
Foetal outcome
 IUFD 11 (27.5)
 Neonatal death 15 (37.5)
 Survival at 28 days after birth 14 (35.0)
  Gestational age at birth of surviving children (n = 14) 31 (27–33)
  Preterm delivery (< 37 weeks) among surviving children (n = 14) 14 (100.0)
 IUGR among surviving children 2 (14.3)
Associated maternal complications
 HELLP syndrome 18 (45.0)
 Eclampsia 6 (15.0)
 Placental abruption 3 (7.5)
 Catastrophic APS 3 (7.5)
  1. APS antiphospholipid syndrome, IQR interquartile range, SLE systemic lupus erythematosus; aNine women had SLE at index pregnancy, whereas 2 patients developed SLE during this pregnancy. Abs antibodies, aPL antiphospholipid, LAC lupus anticoagulant, LDA low dose aspirin, LMWH low-molecular-weight heparin, HELLP haemolysis, elevated liver enzymes, low platelet, IUGR intrauterine growth restriction, IUFD intrauterine foetal death, N number, SD standard deviation